JP2023540599A - Ｃｘｃｒ４及びｉｌ－１０を共発現する間葉系幹細胞並びにその使用 - Google Patents

Ｃｘｃｒ４及びｉｌ－１０を共発現する間葉系幹細胞並びにその使用 Download PDF

Info

Publication number
JP2023540599A
JP2023540599A JP2023515394A JP2023515394A JP2023540599A JP 2023540599 A JP2023540599 A JP 2023540599A JP 2023515394 A JP2023515394 A JP 2023515394A JP 2023515394 A JP2023515394 A JP 2023515394A JP 2023540599 A JP2023540599 A JP 2023540599A
Authority
JP
Japan
Prior art keywords
mscs
cxcr4
cells
expression cassette
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540599A5 (https=
Inventor
ロザリオ エルバス－サルセド
ダミアン ガルシア－オルモ
マリアーノ ガルシア－アランス
ロドリゲス ミリアム エルナンド
ロンセロ フアン アントニオ ブエレン
ゴンサレス ロサ マリア ヤニェス
ガルシア マリア フェルナンデス
サンタラ メルセデス ロペス
フェレイラ マリーナ インマクラダ ガリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Investigacion Biomedica en Red CIBER
Original Assignee
Centro de Investigacion Biomedica en Red CIBER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Investigacion Biomedica en Red CIBER filed Critical Centro de Investigacion Biomedica en Red CIBER
Publication of JP2023540599A publication Critical patent/JP2023540599A/ja
Publication of JP2023540599A5 publication Critical patent/JP2023540599A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023515394A 2020-09-07 2021-09-07 Ｃｘｃｒ４及びｉｌ－１０を共発現する間葉系幹細胞並びにその使用 Pending JP2023540599A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382792.8 2020-09-07
EP20382792.8A EP3964265A1 (en) 2020-09-07 2020-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
PCT/EP2021/074612 WO2022049306A1 (en) 2020-09-07 2021-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof

Publications (2)

Publication Number Publication Date
JP2023540599A true JP2023540599A (ja) 2023-09-25
JP2023540599A5 JP2023540599A5 (https=) 2024-08-02

Family

ID=72473480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515394A Pending JP2023540599A (ja) 2020-09-07 2021-09-07 Ｃｘｃｒ４及びｉｌ－１０を共発現する間葉系幹細胞並びにその使用

Country Status (11)

Country Link
US (1) US20230398152A1 (https=)
EP (2) EP3964265A1 (https=)
JP (1) JP2023540599A (https=)
KR (1) KR20230082622A (https=)
CN (1) CN116507733A (https=)
AU (1) AU2021337798A1 (https=)
BR (1) BR112023004167A2 (https=)
CA (1) CA3194344A1 (https=)
MX (1) MX2023002741A (https=)
SA (1) SA523442866B1 (https=)
WO (1) WO2022049306A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
CN115927178A (zh) * 2022-11-17 2023-04-07 华夏源(上海)生物科技有限公司 一种检测间充质干细胞抑制b细胞分化为浆细胞的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500369A (ja) * 1996-08-30 2001-01-16 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド インターロイキン―１９
JP2013526840A (ja) * 2009-12-21 2013-06-27 ファーマシーネ，インコーポレイテッド 組み換えブチリルコリンエステラーゼおよびその切断型
JP2019523001A (ja) * 2016-07-25 2019-08-22 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074733A1 (en) * 2005-12-09 2009-03-19 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
AU2019291069B2 (en) * 2018-06-19 2026-02-19 Fondazione Centro San Raffaele Production of engineered dendritic cells and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500369A (ja) * 1996-08-30 2001-01-16 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド インターロイキン―１９
JP2013526840A (ja) * 2009-12-21 2013-06-27 ファーマシーネ，インコーポレイテッド 組み換えブチリルコリンエステラーゼおよびその切断型
JP2019523001A (ja) * 2016-07-25 2019-08-22 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"[retrieved on 2025.06.11]", コスモバイオニュース, JPN6025024717, 2017, pages [online], ISSN: 0005732992 *
CHEN W ET AL.: ""[Effect of lentiviral vector mediated CXCR4 gene overexpressed mesenchymal stem cell on the protec", ZHONGHUA XUEYEXUE ZAZHI, vol. 35, no. 10, JPN6025024721, October 2014 (2014-10-01), pages 936 - 40, ISSN: 0005732995 *
M． HERVAS-SALCEDO ET AL.: ""Transient ectopic expression of CXCR4 and IL10 enhances in vivo anti-inflammatory potential of hum", CYTOTHERAPY, vol. 22, no. 5, JPN6025024714, May 2020 (2020-05-01), pages 60, ISSN: 0005732989 *
MIN CK ET AL.: ""IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-vers", BONE MARROW TRANSPLANTATION, vol. 39, no. 10, JPN6025024723, 19 March 2007 (2007-03-19), pages 637 - 45, ISSN: 0005732996 *
WEI CHEN ET AL.: ""CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease"", IMMUNOLOGY LETTERS, vol. 143, no. 2, JPN6025024719, April 2012 (2012-04-01), pages 161 - 169, ISSN: 0005732994 *
ZIQING LIU ET AL.: ""Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector"", SCIENTIFIC REPORTS, vol. 7, no. 1, JPN6025024718, 19 May 2017 (2017-05-19), ISSN: 0005732993 *
タカラ遺伝子導入実験ハンドブック−保存版−, vol. [retrieved on 2025.06.11], JPN6025024716, 2015, ISSN: 0005732991 *
位高 啓史: ""メッセンジャーRNA医薬を実現するDDS開発と疾患治療への応用"", DRUG DELIVERY SYSTEM (DDS), vol. 第31巻, JPN6025024715, 2016, pages 343 - 351, ISSN: 0005732990 *

Also Published As

Publication number Publication date
MX2023002741A (es) 2023-05-26
BR112023004167A2 (pt) 2023-05-09
SA523442866B1 (ar) 2024-05-05
WO2022049306A1 (en) 2022-03-10
CA3194344A1 (en) 2022-03-10
CN116507733A (zh) 2023-07-28
AU2021337798A1 (en) 2023-05-18
US20230398152A1 (en) 2023-12-14
KR20230082622A (ko) 2023-06-08
EP4210834A1 (en) 2023-07-19
EP3964265A1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
JP6251234B2 (ja) Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法
US20210236558A1 (en) Methods for inducing an immune response
JP2023540599A (ja) Ｃｘｃｒ４及びｉｌ－１０を共発現する間葉系幹細胞並びにその使用
Gao et al. Potential long-term treatment of hemophilia A by neonatal co-transplantation of cord blood-derived endothelial colony-forming cells and placental mesenchymal stromal cells
AU2005248352A1 (en) Genetically engineered cells for therapeutic applications
CN104822384A (zh) 用于间充质干细胞诱导的免疫调节的组合物和治疗方法
JP2012100670A (ja) 幹細胞をホーミングさせるためのｃｃｒリガンド
US9592259B2 (en) APC-mediated tolerance induction for therapy of multiple sclerosis
US20220143099A1 (en) Methods to enhance t cell regeneration
CN118240767A (zh) 作为减少或预防转移、治疗自身免疫和炎性病症以及重新平衡免疫环境和失调的小生境的平台的基因修饰的hspc及间充质细胞
US9315558B2 (en) Use of interleukin 10 mRNA transfected macrophages in anti-inflammatory therapies
CN103619342B (zh) 用于治疗肥胖症和/或代谢综合征的方法
KR20220084006A (ko) 세포성 및 체액성 면역을 유도하는 동종이계 t-세포 기반 hiv 백신
KR101699567B1 (ko) ＪｕｎＢ의 발현 또는 활성 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
RU2772132C2 (ru) Лиганды гм-ксф или рецептора гм-ксф для применения при лечении гемобластоза у пациента, перенесшего алло-тгк
JP2006501829A (ja) Ｈｏｘで誘導される増殖を制限する遺伝子をブロックする幹細胞増殖因子およびその方法
WO2023122099A2 (en) Crispr-based gene editing to preserve splicing and expression of foxp3 isoforms 1 and 2
Gabay et al. Interleukin-18 and interleukin-18 binding protein balance: focus on IL-18BP production and IL-18 maturation in macrophage activation syndrome
HK40008045A (en) Methods modulating immunoregulatory effect of stem cells
Stonier Determining the roles of dendritic cells and ICAM-1 in the transpresentation of IL-15 to CD8 T cells
HK1217211A1 (zh) 調節幹細胞的免疫調節作用的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230428

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251118